Advocate Group LLC Has $9.52 Million Position in Pfizer Inc. (NYSE:PFE)

Advocate Group LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 328,830 shares of the biopharmaceutical company’s stock after buying an additional 11,989 shares during the quarter. Pfizer makes up approximately 1.7% of Advocate Group LLC’s investment portfolio, making the stock its 12th largest position. Advocate Group LLC’s holdings in Pfizer were worth $9,516,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Olistico Wealth LLC acquired a new stake in shares of Pfizer during the second quarter worth $25,000. MFA Wealth Advisors LLC bought a new position in shares of Pfizer in the 2nd quarter valued at $29,000. Quarry LP acquired a new position in Pfizer during the 2nd quarter worth approximately $31,000. Creekmur Asset Management LLC bought a new position in shares of Pfizer in the 4th quarter valued at $32,000. Finally, Trivant Custom Portfolio Group LLC grew its holdings in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PFE has been the topic of a number of recent analyst reports. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Thursday, October 3rd. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Barclays boosted their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, UBS Group increased their target price on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Stock Performance

Shares of PFE traded down $0.64 during trading hours on Thursday, hitting $29.55. The stock had a trading volume of 8,631,722 shares, compared to its average volume of 37,294,480. The firm has a market capitalization of $167.45 billion, a PE ratio of -503.25, a PEG ratio of 1.23 and a beta of 0.67. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The stock has a fifty day moving average price of $29.09 and a 200 day moving average price of $28.36. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $33.92.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.67 earnings per share. Analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.69%. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.